Metabolic Marker and Therapeutic Target of Ovarian Cancer Stem Cells

Back to all technologies
Download as PDF
2017-CHEN-67698
The American Cancer Society's 2017 ovarian cancer estimates are 22,440 new cases and 14,080 deaths in the United States. A major reason for the relatively large number of deaths is due to the fact that ovarian cancer is typically discovered in the later stages, making successful treatment more difficult. Currently, there is no reliable early detection test for ovarian cancer for all women. The standard treatment for ovarian cancer is surgery followed by radiation.

Cancer stem cells (CSCs) represent a small population of cancer cells that have the ability to self-renew and initiate tumors in vivo. CSCs are resistant to conventional therapies and are responsible for tumor relapse after chemotherapy and the development of distant metastases. Researchers at Purdue University have developed new techniques that have the potential for discovery and treatment of ovarian cancer stem cells. Using spectrometry imaging, researchers found significantly higher levels of unsaturated lipids in ovarian cancer stem cells as compared to differentiated cancer cells, which look more like normal cells. Lipid desaturases are enriched in CSCs, making them a stable, universal, and functional metabolic marker for CSCs and the target for CSC-specific therapy. This is a promising treatment for ovarian cancer as well as other types of cancer.

Advantages:
-Strong marker potential
-Possible therapeutic target

Potential Applications:
-Ovarian cancer diagnostics
-Ovarian cancer treatment
-Possible use for other cancers
Dec 5, 2018
Provisional-Patent
United States
(None)
(None)

Dec 4, 2017
Provisional-Patent
United States
(None)
(None)

Dec 6, 2016
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org